Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was 250.28B DKK, up 1.8% from the year before. Over ten years it grew 10.6% a year on average. The highest annual figure on record is 250.28B DKK in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 250.28B DKK | +1.8% |
| FY2024 | Dec 31, 2024 | 245.88B DKK | +25.1% |
| FY2023 | Dec 31, 2023 | 196.50B DKK | +32.3% |
| FY2022 | Dec 31, 2022 | 148.51B DKK | +26.8% |
| FY2021 | Dec 31, 2021 | 117.14B DKK | +10.5% |
| FY2020 | Dec 31, 2020 | 106.01B DKK | +4.0% |
| FY2019 | Dec 31, 2019 | 101.93B DKK | +8.2% |
| FY2018 | Dec 31, 2018 | 94.21B DKK | +0.2% |
| FY2017 | Dec 31, 2017 | 94.06B DKK | -0.6% |
| FY2016 | Dec 31, 2016 | 94.60B DKK | +3.1% |
| FY2015 | Dec 31, 2015 | 91.74B DKK | – |
See a number that looks wrong?